Protalix BioTherapeutics (PLX)

What Moves the Stock

1. 01Elelyso market share trends in US and Brazil (key markets with pricing flexibility)
2. 02Clinical trial readouts for PRX-102 (pegunigalsidase alfa) in Fabry disease - potential $500M+ market opportunity
3. 03Partnership announcements or milestone payments from Chiesi or other collaborators
4. 04Regulatory approvals in new geographies for Elelyso or pipeline candidates
5. 05Manufacturing capacity utilization and cost-per-gram improvements in ProCellEx platform
6. 06Elelyso royalties from Pfizer (ex-US territories) - estimated 50-60% of revenue
7. 07Elelyso direct sales and manufacturing revenue from Chiesi USA partnership - estimated 30-40%
8. 08Development and licensing revenue from pipeline candidates (PRX-102, PRX-119) - minimal current contribution

PLX Chart

My Notes

• growth/speculative - The 101.4% six-month return and 57.7% three-month surge indicate momentum-driven trading…
• Rising rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for pre-revenue pipeline…
• Watch on earnings: Quarterly Elelyso prescription volume trends in US (IMS/IQVIA data) and Brazil reimbursement approvals, PRX-102 Phase III BRIGHT trial interim analysis results (expected mid-2026) and FDA filing timeline, Cash burn rate and quarterly operating cash flow to assess financing needs.